Pages that link to "Q46087025"
Jump to navigation
Jump to search
The following pages link to Phase I/II study of ipilimumab for patients with metastatic melanoma (Q46087025):
Displaying 50 items.
- Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? (Q26751230) (← links)
- Immune checkpoint inhibitors: therapeutic advances in melanoma (Q26775591) (← links)
- Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications (Q26779221) (← links)
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis (Q26785746) (← links)
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma (Q27005902) (← links)
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity (Q27012963) (← links)
- Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma (Q28072599) (← links)
- The future of immune checkpoint therapy (Q28259862) (← links)
- The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network (Q28485085) (← links)
- Ipilimumab: from preclinical development to future clinical perspectives in melanoma (Q30240751) (← links)
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination (Q30251438) (← links)
- Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response (Q30907831) (← links)
- Antibody Therapies in Cancer (Q31104000) (← links)
- Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (Q33386521) (← links)
- Melanoma in pediatric, adolescent, and young adult patients (Q33554622) (← links)
- Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1 (Q33579883) (← links)
- IgE-based immunotherapy of cancer: challenges and chances (Q33619979) (← links)
- Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications (Q33621393) (← links)
- Antibodies to watch in 2010 (Q33688243) (← links)
- Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients (Q33708801) (← links)
- Advanced malignant melanoma: immunologic and multimodal therapeutic strategies (Q33717891) (← links)
- Immunologic functions as prognostic indicators in melanoma (Q33835011) (← links)
- Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. (Q33845387) (← links)
- Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy (Q33850467) (← links)
- A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric Cancer (Q33885978) (← links)
- Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). (Q34000700) (← links)
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival (Q34048270) (← links)
- Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial (Q34058870) (← links)
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy (Q34149569) (← links)
- Ipilimumab: first global approval (Q34192041) (← links)
- Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma (Q34209549) (← links)
- CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells (Q34355686) (← links)
- Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. (Q34561877) (← links)
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study (Q34614776) (← links)
- Therapeutic cancer vaccines: are we there yet? (Q34786691) (← links)
- Targeting precision medicine toxicity: recent developments. (Q35019470) (← links)
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (Q35289145) (← links)
- Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy (Q35294382) (← links)
- Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? (Q35419778) (← links)
- Thyroid dysfunction from antineoplastic agents (Q35500038) (← links)
- Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma (Q35614792) (← links)
- Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. (Q35817265) (← links)
- CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma (Q35871798) (← links)
- Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease (Q35913194) (← links)
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma (Q36061606) (← links)
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens (Q36112645) (← links)
- Ipilimumab pharmacotherapy in patients with metastatic melanoma (Q36161313) (← links)
- The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis (Q36192538) (← links)
- Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. (Q36292634) (← links)
- From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer (Q36293995) (← links)